Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Volpe

Showing results (51-60 of 820) with videos related to

Pageof 82
Sort By:
European Heart Journal|August 22, 2025
Weekly Journal Scan: building CONFIDENCE in finerenone/empagliflozin combination for diabetic kidney diseaseDaniela Pedicino, Massimo Volpe
European Heart Journal|July 10, 2025
Weekly Journal Scan: obicetrapib and the revival of cholesteryl ester transfer protein inhibitionRocco Vergallo, Massimo Volpe
Vascular Health and Risk Management|June 30, 2012
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diureticMassimo Volpe, Giuliano Tocci
European Heart Journal|November 10, 2023
More on aldosterone biosynthesis inhibition and resistant hypertension: a Phase-2 study with lorundrostatMassimo Volpe, Leonarda Galiuto
Giornale Italiano Di Cardiologia (2006)|February 26, 2011
[The HEAAL study]Massimo Volpe, Stefano Taddei
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 13, 2010
Rethinking targets of blood pressure and guidelines for hypertension clinical managementMassimo Volpe, Giuliano Tocci
Vascular Health and Risk Management|April 15, 2011
Olmesartan medoxomil for the treatment of hypertension in children and adolescentsGiuliano Tocci, Massimo Volpe
European Heart Journal|September 25, 2024
Weekly Journal Scan: increased incidence of acute myocardial infarction in patients with laboratory-confirmed influenza infectionDaniela Pedicino, Massimo Volpe
European Heart Journal|May 8, 2015
Shooting vascular oxidative stress: new hopes for stroke patients?Massimo Volpe, Francesco Paneni
European Heart Journal|August 6, 2021
A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetesMassimo Volpe, Carlo Patrono
Pageof 82

Showing results (51-60 of 820) with videos related to

Sort By:
Pageof 82
European Heart Journal|August 22, 2025
Weekly Journal Scan: building CONFIDENCE in finerenone/empagliflozin combination for diabetic kidney diseaseDaniela Pedicino, Massimo Volpe
European Heart Journal|July 10, 2025
Weekly Journal Scan: obicetrapib and the revival of cholesteryl ester transfer protein inhibitionRocco Vergallo, Massimo Volpe
Vascular Health and Risk Management|June 30, 2012
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diureticMassimo Volpe, Giuliano Tocci
European Heart Journal|November 10, 2023
More on aldosterone biosynthesis inhibition and resistant hypertension: a Phase-2 study with lorundrostatMassimo Volpe, Leonarda Galiuto
Giornale Italiano Di Cardiologia (2006)|February 26, 2011
[The HEAAL study]Massimo Volpe, Stefano Taddei
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 13, 2010
Rethinking targets of blood pressure and guidelines for hypertension clinical managementMassimo Volpe, Giuliano Tocci
Vascular Health and Risk Management|April 15, 2011
Olmesartan medoxomil for the treatment of hypertension in children and adolescentsGiuliano Tocci, Massimo Volpe
European Heart Journal|September 25, 2024
Weekly Journal Scan: increased incidence of acute myocardial infarction in patients with laboratory-confirmed influenza infectionDaniela Pedicino, Massimo Volpe
European Heart Journal|May 8, 2015
Shooting vascular oxidative stress: new hopes for stroke patients?Massimo Volpe, Francesco Paneni
European Heart Journal|August 6, 2021
A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetesMassimo Volpe, Carlo Patrono
Pageof 82